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Autoimmune liver diseases (AILD) are chronic liver pathologies characterised by fibrosis and 
cirrhosis due to immune-mediated liver damage. In this study, we addressed the question 
whether mucosal-associated invariant T (MAIT) cells, innate-like T cells, are functionally 
altered in patients with AILD and whether MAIT cells can promote liver fibrosis through 
activation of hepatic stellate cells. We analysed the phenotype and function of MAIT cells 
from AILD patients and healthy controls by multi-colour flow cytometry and investigated the 
interaction between human MAIT cells and primary human hepatic stellate cells (hHSCs). 
We show that MAIT cells are significantly decreased in peripheral blood and liver tissue of 
patients with AILD. Notably, MAIT cell frequency tended to decrease with increasing fibrosis 
stage. MAIT cells from AILD patients showed signs of exhaustion, such as impaired IFN 
production and high ex vivo expression of the activation and exhaustion markers CD38, HLA-
DR and CTLA-4. Mechanistically, this exhausted state could be induced by repetitive 
stimulation of MAIT cells with the cytokines IL-12 and IL-18, leading to decreased IFNγ and 
increased exhaustion marker expression. Of note, repetitive stimulation with IL-12 further 
resulted in expression of the pro-fibrogenic cytokine IL-17A by otherwise exhausted MAIT 
cells. Accordingly, MAIT cells from both healthy controls and AILD patients were able to 
induce an activated, pro-inflammatory and pro-fibrogenic phenotype in hHSCs in vitro, 
which was partly mediated by IL-17. Conclusion: Our data provide evidence that MAIT cells 
in AILD patients have evolved towards an exhausted, pro-fibrogenic phenotype and can 
contribute to the development of HSC-mediated liver fibrosis. These findings reveal a 
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Mucosal-associated invariant T (MAIT) cells are innate-like T cells characterised by an 
evolutionarily conserved semi-invariant T cell receptor (TCR) consisting of an invariant  
chain (V7.2-J33/Ja20/J12 in humans) and varying  chains (1, 2), as well as high 
expression of the C-type lectin CD161 (3). Human MAIT cells are abundant in peripheral 
blood, but particularly enriched in liver tissue, representing up to 30% of hepatic CD3+ T cells 
(3, 4). The ability of MAIT cells to recognize microbial-derived vitamin B metabolites 
presented on the major histocompatibility complex class I-related molecule MR1 (5) allows 
MAIT cells to detect various strains of bacteria and yeasts in vitro and in vivo (6, 7). In line 
with their innate-like nature, MAIT cells are also activated by the pro-inflammatory 
cytokines IL-12 and IL-18 in a TCR independent manner (8). Once activated, MAIT cells exert 
cytotoxic properties, and secrete pro-inflammatory cytokines such as IL-17 and IFN(3, 6). 
Besides their role in mediating anti-microbial defence, MAIT cells have been implicated in 
the development of non-infectious diseases, including autoimmune diseases such as 
multiple sclerosis (9, 10) and inflammatory bowel diseases (11), suggesting that MAIT cells 
can orchestrate inflammatory responses in absence of infection. AILD, i.e. primary sclerosing 
cholangitis (PSC), primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) are 
characterized by chronic hepatic inflammation, eventually leading to the development of 
liver fibrosis and cirrhosis, associated with a high risk of morbidity and mortality (12). The 
pathogenesis of AILD is poorly understood, although it is becoming increasingly clear that 
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environmental triggers and genetic aberrations of immunoregulatory pathways contribute 
to chronic inflammation and T cell mediated damage in the liver (12). Genome-wide 
association studies recently demonstrated that variations in the IL-12 pathway are 
associated with the development of PBC (13). A potential role of IL-12 in AILD development 
is further supported by murine studies, in which deletion of the IL-12 subunit p40 
ameliorated the development of autoimmune cholangitis (14), and overexpression of IL-12 
resulted in development of an AIH-resembling liver inflammation (15). Central to the 
development of liver fibrosis by inflammation is the activation of hepatic stellate cells 
(HSCs), non-parenchymal liver cells that transform into extracellular matrix (ECM) secreting 
myofibroblasts following activation (16). HSC activation and the subsequent development of 
liver fibrosis are mediated by IL-17 in murine models, evident by ameliorated liver fibrosis in 
IL-17RA-/- mice in vivo, as well as increased collagen secretion and expression of -SMA, IL-6 
and TGF- by IL-17 stimulated HSCs in vitro (17, 18). 
However, whether MAIT cell derived IL-17A can mediate HSC activation in humans remains 
unclear. Here, we investigated the role of human MAIT cells in fibrosis development and 
HSC activation in AILD. Our data show that MAIT cells are severely reduced in peripheral 
blood and liver tissue from AILD patients, and the remaining MAIT cells show features of 
chronic activation and functional exhaustion, which could be induced by long-term exposure 
to the pro-inflammatory cytokines IL-12 and IL-18. Despite their exhausted state, MAIT cells 
produce large amounts of IL-17A in response to repetitive stimulation with IL-12. MAIT cells 
are further able to activate HSCs, leading to HSC proliferation and the expression of pro-
fibrogenic and pro-inflammatory genes in HSCs in an IL-17 and cell-cell contact dependent 
manner. Our data reveal a crucial role of MAIT cells in liver fibrosis development and 
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provide important mechanistic insights that will help to design novel therapeutic 
approaches targeting HSC activation in fibrosis. 
 
 
Material and Methods  




This study was fully approved by the Royal Free Hospital ethical board and all participants 
gave written informed consent before sample collection.  
 
Primary Cell Isolation 
All tissue samples were obtained from patients or healthy volunteers at the Royal Free 
Hospital. See table S1 for patient information. PBMCs were isolated using Ficoll-Paque Plus 
(GE Healthcare, Uppsala, Sweden) gradient centrifugation. Liver associated lymphocytes 
were isolated from cirrhotic liver tissue derived from explanted livers of patients with AILD, 
from wedge sections of patients undergoing liver surgery in the absence of background liver 
disease, or from healthy liver explants considered unsuitable for transplantation (enabled by 
NHSBT). Primary human HSCs (hHSC) were isolated from wedge sections of human liver 
tissue as described before (19). 
 
Flow cytometric analysis 
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Cells were stained for surface markers and intracellular markers (see supplementary 
information for a full list of antibodies). Dead cells were excluded using live/dead fixable UV 
dead stain kit (Invitrogen, Carlsbad, CA). For staining of intracellular markers, cells were 
fixed and permeabilized using Intracellular Fixation and Permeabilisation Buffer 
(ebioscience, San Diego, CA), or human FOXP3 buffer set (BD Biosciences, San Jose, CA). 
CountBright Absolute Counting Beads (Molecular Probes, Eugene, OR) were used to 
determine absolute numbers of MAIT cells in peripheral blood. Samples were acquired with 




Transient elastography was performed to measure liver stiffness using FibroScan® 
(Echosens). Fibrosis stage was defined using previously described cut-offs with F0-1: 
stiffness <7.1 kilopascal (kPa), F2:  7.1-9.4 kPa, F3: 9.5-12.4 kPa, F4: >12.5 kPa (20). 
 
In vitro stimulation assays 
PBMCs or purified V7.2+ cells, enriched by magnetic cell separation (see supplementary 
information) were stimulated in vitro with 50ng/ml phorbol 12-myristate 13-acetate (PMA) 
and 1M Ionomycin (both Sigma Aldrich, St. Louis, MO), or Dynabead Human T-activator 
CD3/CD28 (Invitrogen, Carlsbad, CA) for 16 hours. PMBCs or purified V7.2+ cells were 
stimulated in vitro with 50ng/ml IL-1, IL-18 (R&D systems, Minneapolis, MN), or IL-12 
(Miltenyi Biotec, Bergisch Gladbach, Germany) for 24 hours (short-term stimulation) or 
every 24 hours for 72 hours (long-term, repetitive stimulation). Brefeldin A and Monensin 
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(both ebioscience, San Diego, CA) were added for the last 4 hours of culture when 
intracellular cytokine expression was analysed by flow cytometry. 
 
In vitro co-culture of MAIT cells and HSCs 
V7.2+ cells were purified from PBMCs by magnetic cell separation and added to cultured 
primary human HSCs for 48 hours. Dynabead Human T-activator CD3/CD28 (Invitrogen, 
Carlsbad, CA), or 2g/ml IL-17RA/IL-17R antibody (R&D systems, Minneapolis, MN) was 
added where indicated. After extensive washing to remove MAIT cells, HSC gene expression 
was determined by RT-PCR and HSC proliferation was assessed using BrdU Cell proliferation 
ELISA (Roche, Basel, Switzerland). 
 
Statistical analysis 
Statistical analyses were performed using Microsoft Excel or Graph Pad Prism. Values are 
expressed as mean +/- standard deviation (SD), mean +/- standard error of the mean (SEM), 
or mean +/- 95% confidence interval (CI) as indicated in the figures. Statistical significance 




MAIT cells are significantly declined and phenotypically altered in AILD patients 
Human MAIT cells are defined by expression of CD3, CD161 and V7.2 TCR (2, 3) 
(Supplementary figure 1a). To investigate the MAIT cell compartment in patients with PSC, 
PBC and AIH, we first determined the frequency of CD3+ CD161++ V7.2+ MAIT cells 
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(hereafter referred to as MAIT cells) by flow cytometry in peripheral blood and liver tissue of 
AILD patients and healthy controls. MAIT cells were severely reduced in frequency and 
absolute number in peripheral blood (Figure 1a) and liver tissue (Figure 1b) of AILD patients, 
regardless of the subtype of disease. Moreover, MAIT cell frequency was significantly 
decreased in peripheral blood of patients with non-alcoholic steatohepatitis (NASH) (Figure 
1c), suggesting that MAIT cells are decreased in various types of chronic liver disease. The 
significant decrease in frequency was specific to MAIT cells in AILD, since the frequency of 
other conventional and non-conventional lymphocyte populations was unchanged 
(Supplementary figure 1b). MAIT cells can be divided into subsets based on CD4 and CD8 
expression, with the majority of MAIT cells being CD8+ or CD4/CD8-/-(2). In AILD, all subsets 
of MAIT cells were significantly reduced in peripheral blood (Supplementary figure 1c). CD8+ 
MAIT cells represented the major subset in peripheral blood and liver tissue of healthy 
controls and AILD patients (Figure 1d-e), although a relative increase of CD4+ MAIT cells was 
observed (Figure 1d-e) in AILD patients. Moreover, the frequency of MAIT cells in peripheral 
blood of AILD patients decreased with increasing fibrosis stage and liver tissue stiffness 
assessed by transient elastography (Figure 1f), suggesting that the frequency of MAIT cells 
declines with disease progression in AILD. To analyse the localisation of MAIT cells in the 
liver, V7.2 TCR was immunohistochemically detected in liver tissue of patients and 
controls. Whereas MAIT cells localised around the portal tracts and in the parenchyma in 
normal livers (Figure 2a), MAIT cells were observed in inflammatory infiltrates around portal 
tracts and fibrotic septae in diseased livers (Figure 2a). Quantification of V7.2+ cells 
revealed a marked decrease of MAIT cell numbers in liver tissue of PSC and PBC patients 
compared to healthy controls, while MAIT cells were unchanged in highly inflamed AIH and 
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NASH (Figure 2b). Taken together, these data establish that the frequency of MAIT cells is 
severely reduced in peripheral blood and liver tissue of patients with AILD. 
 
MAIT cells from AILD patients show features of chronic activation and functional 
exhaustion 
As AILD are characterized by chronic inflammation (12), we next probed MAIT cells from 
patients with AILD for features of immune activation and exhaustion ex vivo. Whereas the 
surface expression of the inhibitory receptor PD-1 was comparable in MAIT cells from 
peripheral blood of patients and healthy controls (Supplementary figure 2a), levels of CTLA-
4 and TIM-3 were higher in MAIT cells from patients with AILD. Importantly, MAIT cells from 
AILD patients showed higher expression of CD39, a marker of terminal and irreversible T cell 
exhaustion (21). In line with increased expression of exhaustion markers, MAIT cells from 
patients with AILD showed significantly higher levels of the activation marker CD38, and 
markedly increased expression of CD69 and HLA-DR (Figure 3a), indicating that MAIT cells in 
peripheral blood of AILD patients are chronically activated. Mirroring the findings in MAIT 
cells from peripheral blood, hepatic MAIT cells from AILD patients showed significantly 
higher levels of CTLA-4 compared to healthy controls (Figure 3b), while the levels of other 
activation and exhaustion markers were similar (Supplementary figure 2b). Of note, MAIT 
cells isolated from peripheral blood of NAFLD/NASH patients showed increased expression 
of the activation and exhaustion markers PD-1, CD39, CD38 and HLA-DR as well 
(Supplementary figure 2c), suggesting that MAIT cell activation also occurs in non-
autoimmune liver disease. As T cell exhaustion is associated with a loss of effector function 
(22), we next assessed the ability of AILD MAIT to produce effector cytokines and cytolytic 
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proteins in response to stimulation. Compared to healthy controls, IFN production was 
significantly impaired in MAIT cells from patients with PBC, and markedly reduced in MAIT 
cells from patients with PSC and AIH following in vitro stimulation with PMA/Ionomycin 
(Figure 3c). Moreover, MAIT cells from AILD patients showed higher granzyme B (GrzB) 
levels at steady state, but failed to significantly upregulate GrzB expression upon CD3/CD28 
bead stimulation, compared to healthy controls (Figure 3d). In contrast, IL-17A and 
TNFproduction in response to such stimulation remained unchanged (Figure 3e and 
supplementary figure 2d). These data strongly suggest that MAIT cells in AILD are highly 
activated and show signs of early functional exhaustion, while maintaining their ability to 
express IL-17A and TNF. Correlation analyses further revealed a negative correlation 
between MAIT cell frequency in AILD and expression of activation markers such as CD38 and 
HLA-DR as well as exhaustion markers such as CTLA4, CD39 and TIM-3 (Figure 3f and 
supplementary figure 2e). These data indicate that the low frequency of circulating MAIT 
cells in AILD patients may result from reduced survival of MAIT cells as a consequence of 
chronic activation and exhaustion in vivo.  
 
Long-term stimulation with IL-12+IL-18 drives MAIT cell exhaustion and cell death 
High expression of the cytokine receptors IL-12R and IL-18R by MAIT cells allows for TCR-
independent stimulation of MAIT cells with IL-12 and IL-18 resulting in IFN expression (8). 
In line with this, we observed high levels of IL-12R and IL-18R expression on MAIT cells from 
peripheral blood and liver tissue of healthy controls and AILD patients (Supplementary 
figure 3 a-b). AILD are characterized by persistent liver inflammation and high serum levels 
of pro-inflammatory cytokines such as IL-1, IL-12 and IL-18 (23, 24). We mimicked this 
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chronic inflammatory setting by repetitively stimulating MAIT cells with IL-12, IL-18 and IL-
1in vitro, and assessed their ability to express IFN. Both short-term (24 hours) and 
repetitive, long-term (72 hours) in vitro stimulation with a combination of IL-12 and IL-18, 
but not IL-12 or IL-18 alone, induced a robust IFN response in MAIT cells from healthy 
controls and AILD patients, which was not further exacerbated by additional IL-1 (Figure 
4a), demonstrating that the response to cytokine mediated stimulation is maintained in 
MAIT cells from patients with AILD, despite their exhausted phenotype. To exclude effects 
from bystander immune cells in the stimulated PBMC pool on the induction of IFN 
expression in MAIT cells, purified V7.2+ MAIT cells from healthy controls were stimulated 
with IL-1β, IL-12 and IL-18 next. Like in PBMCs, IL-12 + IL-18 specifically induced expression 
of IFN in purified MAIT cells (Figure 4b), indicating that IL-12 + IL-18 can directly stimulate 
MAIT cell activation. Interestingly, IFN expression of MAIT cells from healthy controls and 
AILD patients significantly decreased following repetitive, long-term stimulation with IL-12 + 
IL-18 in vitro (Figure 4c), despite constant levels of IL-12 receptor expression 
(Supplementary figure 4a). Since decreasing IFN expression is a hallmark of T cell 
exhaustion, we next tested the expression of inhibitory receptors in cytokine-stimulated 
MAIT cells. Following repetitive stimulation with IL-12 + IL-18, we observed increased PD-1 
and TIM-3 expression, as well as significantly higher expression of CD39 in MAIT cells from 
healthy controls (Figure 4d) and AILD patients (Supplementary figure 4b). Moreover, the 
frequency of live MAIT cells declined in response to repetitive stimulation with IL-12 + IL-18, 
whereas the frequency of CD3+ cells remained constant (Supplementary figure 4c), showing 
that MAIT cell loss was specific and not accompanied by general T cell death in culture. 
These data suggest that repetitive stimulation with the pro-inflammatory cytokines IL-12 + 
IL-18 can to drive MAIT cell exhaustion and cell death in vitro. In order to investigate 
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possible mechanisms of MAIT cell exhaustion in AILD in vivo, we analysed CD3 expression in 
hepatic MAIT cells as a surrogate marker for antigen exposure (25). Indeed, hepatic AILD 
MAIT cells showed significantly lower expression of CD3 compared to healthy controls 
(Figure 4e), suggesting that MAIT cells are chronically exposed to their cognate antigen in 
AILD livers in vivo. Of note, exposure to bacterial antigens has been shown to induce 
downregulation of the transcription factors eomesodermin (EOMES) and T-bet in MAIT cells, 
which has been linked to MAIT cell exhaustion (26). We therefore analysed T-bet and 
EOMES expression in MAIT cells ex vivo. Indeed, MAIT cells from peripheral blood of AILD 
patients expressed significantly lower levels of EOMES and lower levels of T-bet compared 
to healthy controls (Figure 4f). These data suggest that MAIT cell exhaustion in AILD might 
be induced by chronic exposure to both inflammatory cytokines and bacterial antigen and 
may be regulated by downregulation of T-bet and EOMES. 
 
Repetitive IL-12 stimulation significantly induces the expression of the pro-fibrogenic 
cytokine IL-17A in MAIT cells 
Previous reports have described the induction of IFN expression in MAIT cells in a PBMC 
pool by IL-12 + IL-18 (8, 27). However, to our knowledge, there is no evidence for cytokine-
mediated stimulation of IL-17A expression, which has been shown to contribute to fibrosis 
development in animal models and to stimulate HSC activation in vitro (17, 18). 
Interestingly, no IL-17A expression was detected in MAIT cells after short-term (24 hours) 
cytokine stimulation (Figure 5a). In contrast, repetitive, long-term (72 hours) stimulation 
with IL-12 alone or in combination with other cytokines resulted in a significant increase in 
IL-17A+ MAIT cells from healthy controls (Figure 5b). Similarly, repetitive stimulation of 
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purified MAIT cells with IL-12 significantly induced IL-17A expression in MAIT cells (Figure 
5c), demonstrating that the observed IL-17A expression resulted from direct IL-12 signalling 
on MAIT cells. Along these lines, long-term stimulation with IL-12 induced IL-17A expression 
in MAIT cells from AILD patients (Figure 5d), which was indistinguishable from IL-17A 
expression in MAIT cells from healthy controls (Figure 5e). These data demonstrate that 
MAIT cells from AILD patients, despite their exhausted phenotype, produce IL-17A in 
response to repetitive stimulation with inflammatory cytokines. In order to elucidate a 
mechanism through which IL-12 stimulates IL-17A expression in MAIT cells, we analysed 
expression of the transcription factor retinoic acid-related orphan receptor T (RORt), 
which is required for the expression of IL-17 in T cells (28). We detected significantly 
increased levels of RORt expression in MAIT cells from healthy controls (Figure 5f) and AILD 
patients (Supplementary figure 5a) following 24 hour IL-12 stimulation, which was sustained 
in MAIT cells stimulated for 72 hours (Figure 5f and supplementary figure 5a). These data 
indicate that IL-12 signalling induces robust upregulation of RORt expression in MAIT cells, 
which may mechanistically enable IL-17A expression. 
 
MAIT cells stimulate hHSC proliferation and induce an activated, pro-inflammatory HSC 
gene signature in a cell-cell contact and IL-17 dependent manner 
Chronic hepatic inflammation in AILD results in the development of liver fibrosis (12) as a 
consequence of HSC activation (29), which can be mediated by IL-17A in murine models (17, 
18). As we observed IL-17A expression by MAIT cells upon repetitive stimulation with IL-12, 
we hypothesised that human MAIT cells are able to activate HSCs in vitro, and analysed 
primary human HSC (hHSC) proliferation in the presence of MAIT cells. Co-culture of hHSCs 
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with MAIT at a ratio of 1:1 hHSCs:MAIT cells resulted in a significant increase in hHSC 
proliferation (Figure 6a). We next investigated gene expression in hHSCs co-cultured with 
MAIT cells. MAIT cells induced increased expression of the activation marker α-SMA (ACTA2) 
in hHSCs, as well as a significant increase in expression of the pro-fibrogenic genes collagen 
1 (Col1A1), lysyl oxidase (LOX) and TIMP-1 (Figure 6b). Similarly, expression of pro-
inflammatory genes, such as IL-1, IL-6, IL-8 and CCL2 was significantly increased in hHSCs 
following 48h co-culture with MAIT cells (Figure 6b). We next investigated whether MAIT 
cells from AILD patients, although exhausted, were able to increase the expression of genes 
typical of HSC activation. Similar to MAIT cells from healthy controls, MAIT cells from AILD 
patients induced gene expression in HSCs regardless of the type of disease (Figure 6c) and 
stimulated hHSC proliferation (Supplementary figure 6a), indicating that MAIT cells from 
AILD patients retain their pro-fibrogenic potential. Of note, MAIT cells isolated from patients 
with different fibrosis stages showed no difference in their ability to induce hHSC 
proliferation and gene expression. Moreover, similar to AILD MAIT cells, NASH MAIT cells 
stimulated pro-inflammatory gene expression in HSCs (Figure 6d). These data indicate that 
MAIT cells are able to further promote the features of hHSC activation in vitro, a process 
that contributes to fibrosis development in the liver in vivo (29). In order to determine 
whether IL-17A mediated hHSC activation by MAIT cells, we tested the effect of IL-17RA 
blockade on hHSC gene expression in our co-culture system. As IL-17 did not induce 
expression of pro-fibrogenic genes in hHSCs in vitro, but was sufficient to induce expression 
of pro-inflammatory genes, such as IL-1, IL-6, IL-8 and CCL2 in hHSCs (Supplementary figure 
6b), we tested the effect of IL-17R blockade on pro-inflammatory gene expression. Indeed, 
blocking IL-17R resulted in a decrease of IL-1, IL-8 and CCL2 expression in hHSCs co-
cultured with MAIT cells (Figure 6e), indicating that hHSC activation by MAIT cells is partly 
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mediated by IL-17A. We next investigated whether hHSC activation by MAIT cells also 
requires cell-cell contact. MAIT cells and hHSCs were either co-cultured allowing for cell-cell 
contact, or in a transwell system, thereby preventing cellular contact but allowing the 
exchange of soluble mediators. Separation of MAIT cells and hHSCs in the transwell system 
partly reversed upregulation of IL-1, IL-8 and CCL2 expression and abrogated upregulation 
of IL-6, LOX and TIMP-1 expression in HSCs (Figure 6f). Taken together, these data suggest 
that MAIT cells from healthy individuals, as well as from patients with chronic liver disease, 




The pathogenesis of AILD development is still incompletely understood. Yet, it has recently 
become clear that chronic inflammation observed in AILD results from inadequate immune 
activation and a breakdown of self-tolerance in the liver, culminating in T cell mediated liver 
damage and fibrosis development (12), which is characterized and driven by HSC activation 
(29). Here, we demonstrate a potential role of MAIT cells in fibrosis development in AILD. 
Irrespective of the type of disease, MAIT cells in AILD patients showed phenotypical and 
functional features of cellular exhaustion and were severely reduced in number. The severe 
decline of MAIT cells observed in both peripheral blood and liver tissue of AILD patients 
probably results from chronic activation and cellular exhaustion, which is commonly 
characterized by a hierarchical loss of effector function, followed by cell death (30). T cell 
exhaustion arises from chronic exposure to various stimuli, e.g. chronic infection with 
pathogens (31, 32), long-term exposure to viral antigen (22), antigen-release from tumours 
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(33), or long-term inflammation and chronic exposure to inflammatory cytokines (34). Here, 
we show that exhaustion of human MAIT cells can be driven by long-term stimulation with 
the pro-inflammatory, third-signal cytokines IL-12 + IL-18. As both IL-12 and IL-18 levels are 
elevated in serum of patients with AILD (23, 24), it seems plausible that MAIT cells are 
chronically exposed to IL-12 + IL-18 in AILD patients, providing a potential mechanistic 
explanation for the observed exhaustion of MAIT cell in AILD patients in vivo. Moreover, we 
show that MAIT cells from AILD patients express significantly lower levels of CD3 as well as 
of the transcription factor EOMES, both of which can be induced by antigen exposure (25, 
26). Thus, it is likely that additional mechanisms such as long-term exposure to bacterial-
derived antigen contribute to MAIT cell activation and exhaustion in vivo. This is of special 
importance considering that AILD cirrhosis is often characterized by bacterial translocation 
from the gut to the liver (35), which might provide a source of bacterial-derived riboflavin 
derivatives that specifically activate MAIT cells (36, 37). 
The pro-inflammatory cytokine IL-17A is regarded as a key cytokine for the development of 
tissue-specific autoimmune disorders and has recently been shown to be involved in hepatic 
fibrosis development in both non-autoimmune mediated liver disease (18, 38, 39) and AILD 
(13, 38-41). PSC, PBC and AIH patients show elevated serum levels of IL-17 (42-44), along 
with infiltration of IL-17+ cells into the liver parenchyma (42, 45). Furthermore, the number 
of liver infiltrating IL-17+ cells correlates with hepatic inflammation and fibrosis in AIH (46). 
Although IL-17 can be secreted by conventional T helper 17 (Th17) cells at high levels (47), 
up to now it is unclear which cells contribute to IL-17 production during human liver 
inflammation, especially in AILD. Interestingly, MAIT cells represent more than 60% of IL-17+ 
cells in the liver (4), suggesting that IL-17 in the liver in vivo might be predominantly derived 
from MAIT cells rather than Th17 cells. As MAIT cells from AILD patients, despite exhibiting 
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clear features of chronic exhaustion, retain their ability to express the cytokine IL-17A ex 
vivo, it seems likely that MAIT cells constantly produce IL-17A in the liver of AILD patients. 
Furthermore, we describe for the first time that chronic stimulation of MAIT cells by the 
innate, pro-inflammatory cytokine IL-12 stimulates IL-17A expression in MAIT cells. IL-12 
predominantly signals through activation of the transcription factors signal transducer and 
activator of transcription (STAT) STAT1, STAT3, STAT5, and in particular STAT4 (48, 49), 
leading to IFN expression (50). However, STAT3 signalling can further induce the expression 
of the transcription factor RORT, which regulates IL-17 expression (28) and is constitutively 
expressed in MAIT cells (3). We show that IL-12 stimulation induces significant upregulation 
of RORt in MAIT cells. Therefore, the observed expression of IL-17 in MAIT cells following 
prolonged exposure to IL-12 might result from “non-classical” IL-12 signalling, mediated 
through STAT3-regulated RORT induction, although further experiments are necessary to 
fully confirm this hypothesis. 
Activation of HSCs is a key event in the development of liver fibrosis, as HSCs transform into 
hyper-proliferative, myofibroblast-like cells producing large amounts of ECM proteins upon 
activation (29), thereby leading to the formation of liver fibrosis and cirrhosis (29). In murine 
model of liver fibrosis, it has been demonstrated that fibrosis development depends on IL-
17A in vivo, and that IL-17A induced HSC activation in vitro (18). However, whether IL-17 
contributes to fibrosis development through activation of HSCs in human AILD has not been 
investigated so far. Our findings show for the first time that MAIT cells induce HSC 
proliferation and an activated, pro-fibrogenic and pro-inflammatory phenotype in primary 
human HSCs in vitro. Interestingly, despite an exhausted phenotype, MAIT cells from AILD 
patients, regardless of the donor’s fibrosis stage, retain their ability to secrete IL-17A and 
are equally able to induce HSC activation. These data suggest that MAIT cells may contribute 
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to fibrosis development in AILD in vivo throughout disease progression. Moreover, we show 
that MAIT cells isolated from NASH patients are highly activated and able to induce HSC 
activation in vitro as well, suggesting a rather general pro-fibrogenic role of MAIT cells in 
chronic liver disease. Mechanistically, the pro-fibrogenic activation of HSCs by MAIT cells 
depends on IL-17A but also involves direct cell-cell contact between MAIT cells and HSCs, at 
least in vitro.  
Taken together, our findings demonstrate a role for IL-17 producing MAIT cells as pro-
fibrogenic cellular mediators in AILD, which could serve as a potential therapeutic target for 
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Figure 1: MAIT cell frequency is significantly reduced in peripheral blood and liver tissue of 
patients with AILD.  
MAIT cell frequency (n=15 (HC), n=18 (PSC), n=14 (PBC), n=10 (AIH)) and absolute number in 
peripheral blood (a, c) and liver tissue (b). Phenotype of MAIT cells in peripheral blood (d) 
and liver tissue (e). (f) Spearman correlation between MAIT cell frequency in peripheral 
blood of AILD patients and fibrosis stage or liver stiffness (n=70). (a)-(e) Data represent 
mean +/- SD, pooled data from 4 independent experiments. *p< 0.05, **p<0.01, 
***p<0.001, ****p<0.0001 vs. healthy controls, assessed by One-way ANOVA with Tukey’s 
multiple comparisons test (a, d) or Mann-Whitney test (b, c, e). HC = healthy control 
 
Figure 2: MAIT cells localise around portal tracts and fibrotic septae in AILD livers 
(a) Haematoxylin & Eosin (H&E), Sirius Red and immunohistochemistry of healthy and 
diseases liver tissue. (b) Number of V7.2+ MAIT cells/high power filed (HPF), each symbol 
represents one individual. Data represent mean +/- SD, *p< 0.05 vs. healthy control (HC), 
assessed by Kruskal-Wallis test. 
 
Figure 3: AILD MAIT cells show signs of exhaustion and express IL-17A. 
Ex vivo expression of surface markers in MAIT cells from (a) peripheral blood and (b) liver. 
Intracellular IFN(c), GrzB (d), IL-17A and TNF- (d) expression in MAIT cells following in 
vitro PMA/Ionomycin (c, e) or CD3/CD28 bead (d) stimulation for 16h. (e, f) Spearman 
correlation between MAIT cell frequency in peripheral blood of AILD patients and 
expression of activation markers and inhibitory receptors. (a, c) Data represent mean +/- 
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SEM, (b, d-e) mean +/- SD, pooled data of at least 3 independent experiments. *p< 0.05 vs. 
healthy control, ****p<0.0001 vs. unstimulated control, assessed by Mann-Whitney test (a, 
b, e), or one-way ANOVA with Tukey’s or Dunn’s multiple comparisons test (c, d). HC = 
healthy control 
 
Figure 4: Long-term exposure to pro-inflammatory cytokines drives MAIT cell exhaustion. 
Intracellular IFN expression of (a) MAIT cells in a PMCB pool (n = 12) or (b) purified V7.2+ 
cells (n=3) stimulated with IL-1, IL-12 and IL-18 (24-72h). (c) Intracellular IFN expression of 
MAIT cells in a PBMC pool stimulated with IL-12+IL-18 (72h) (n=12). (d) Surface expression 
of inhibitory receptors in peripheral blood MAIT cells from healthy controls stimulated with 
IL-12 + IL-18 (24-72h). (e) CD3 expression in hepatic MAIT cells. (f) EOMES and T-bet 
expression in peripheral blood MAIT cells. Data represent mean +/- SEM (a, c), or mean +/- 
SD (b, d-f), pooled data from at least 3 independent experiments.*p< 0.05, **p<0.01, 
***p<0.001, ****p<0.0001 vs. no stimulation, healthy control, or as indicated, assessed by 
2-way ANOVA and Sidak’s multiple comparisons test (a-d), or Mann-Whitney test (e-f). 
 
Figure 5: Repetitive IL-12 stimulation induces IL-17A expression in MAIT cells 
Intracellular IL-17A expression in MAIT cells in a PBMC pool from (a-b) healthy controls (HC) 
(n=12) and (d) AILD patients (n=26) stimulated with IL-1, IL-12 and IL-18 for (a) 24h or (b, d) 
24 -72h. (c) Intracellular IL-17A expression of purified V7.2+ MAIT cells following cytokine 
stimulation (24-72h) (n=3). (e) Intracellular IL-17A expression of MAIT cells from AILD 
patients and HC following cytokine stimulation (72h) (HC n=9, AILD n=26). (f) RORt 
expression in MAIT cells following IL-12 stimulation (24-72h). Data represent mean +/- SEM 
(a-b, d-e) pooled data from 4 independent experiments. (c, f) Data represent mean +/- SD, 
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data from at least 2 independent experiments. *p< 0.05, **p<0.01, ***p<0.001, 
****p<0.0001 vs. no stimulation or as indicated, assessed by 2-way ANOVA and Sidak’s 
multiple comparisons test (a-e) or paired t-test and Kruskal-Wallis test (f). 
 
Figure 6: MAIT cells are able to stimulate HSC activation in a cell-cell contact and IL-17 
dependent manner 
(a) BrdU incorporation (n=4) and (b)-(d) gene expression of human HSCs after 48h co-culture 
with V7.2+ MAIT cells from (a-b) healthy controls (HC), (c) AILD and (d) NASH patients. 
Gene expression of hHSCs after co-culture with V7.2+ MAIT cells from healthy controls 
with IL-17R antibody (e) and in transwell system (f). (a, c-f) Data represent mean +/- SD *p < 
0.05, ***p<0.001. ****p<0.0001 vs. unstimulated control, assessed by one-way ANOVA and 
Tukey’s or Dunn’s multiple comparisons test, representative data from 3 independent 
experiments. (b) data represent mean +/- 95% CI, *p = 0.05 vs. unstimulated control, pooled 





Antibodies for flow cytometry 
Surface markers: CD3 FITC (HIT3a), CD4 PE (OKT4), CD8 APC (SK1) (ebioscience, San Diego, 
CA), CD4 PE-CF594 (RPA-T4), HLA-DR FITC (G46-6), CD152/CTLA-4 BV786 (BNI3), CD212/IL-
12R APC (2.4e6), CD16 APC-H7 (3G8), CD56 PE-Cy7 (B159), iNKT PE (6B11), V2 FITC (B6), 
Granzyme B A700 (GB11) (BD Biosciences, San Jose, CA), CD161 BV605 (HP-3G10), V7.2 
BV421 (3C10), V7.2 PE (3C10), CD279/PD-1 PE (EH12.2H7), CD69 PE dazzle 594 (FN50), 
CD38 PE dazzle 594 (HIT2), CD39 BV421 (A1), CD218/IL-18R PE (H44), CD3 BV605 (OKT3), 
V7.2 PE-Cy7 (3C10) (Biolegend, San Diego, CA), CD161 PE (191B8) (Miltenyi Biotec, 
Bergisch Gladbach, Germany) and TIM3 PE (344823) (R&D systems, Minneapolis, MN). 
Intracellular markers: IFN APC-Cy7 (4S.B3), IL-17A PerCP/Cy5.5 (BL168), TNF PE-Cy7 
(MAb11) (Biolegend, San Diego, CA), EOMES PE-eFlour610 (WD1928), T-bet eFlour660 
(4B10) (ebioscience, San Diego, CA), RORt BV421 (Q21-559) (BD Biosciences, San Jose, CA). 
 
Isolation of Liver associated Lymphocytes 
Briefly, liver associated lymphocytes were isolated from 20g cirrhotic liver tissue using 
collagenase type IV (Sigma Aldrich, St. Louis, MO) digestion (0.5g/ml, 10 min, 37° C), or 
from 20g healthy liver tissue, and passed through a metal mesh. After incubation with 
DNase I (Sigma Aldrich, St. Louis, MO) (0.5g/ml, 10 min, 37° C) cell suspension from either 
type of liver tissue was washed extensively and liver associated lymphocytes were enriched 
using Ficoll-Paque Plus and 40% Percoll (both GE Healthcare, Uppsala, Sweden) gradient 
centrifugation (1). 
 
Isolation of hHSCs 
Briefly, 10g of liver tissue was digested with 0.01% Collagenase type IV, 0.05% Pronase and 
0.001% DNase I (all Sigma Aldrich, St. Louis, MO). The homogenate was washed and 
Optiprep 11.5% (Sigma Aldrich, St. Louis, MO) gradient centrifugation was performed to 
enrich HSCs. The obtained HSC were cultured in Iscove’s Modified DMEM (IMDM), 
supplemented with 20% foetal bovine serum (FBS), 2 mM Glutamine, 1X nonessential amino 
acids, 1.0 mM sodium pyruvate, 1X antibiotic-antimycotic (all from Life Technologies, 
Carlsbad, CA), referred to as complete hHSC medium (CM) hereinafter. Each hHSC 
preparation was maintained under standard conditions in a humidified incubator under 5% 
CO2 at 37°C. Experiments described in this study were performed with hHSC cultured in CM 
of at least three cell preparations used between passage 2 and 9. 
 
Transient elastography 
The 5 MHz ultrasound transducer probe was placed perpendicularly to the skin between the 
ribs over the right lobe of the liver, the patient lying in dorsal decubitus with the right arm in 
maximal abduction. All patients underwent a fasting period of at least 3 hours prior to 
measurements. The M or XL probe was used according to patients’ physical constitution. 
Liver stiffness was expressed in kilopascal (kPa) and a test was considered valid, when at 
least 10 successful measurements with a success rate of >60% and an interquartile range 
(IQR) <30% were obtained. 
Magnetic cell separation 
V7.2+ MIT cells were isolated using a V7.2 PE antibody (clone: 3C10) (biolegend, San 
Diego, CA). Cells were labelled with anti V7.2 PE 1:100 for 30 min on ice and incubated 
with anti-PE beads and purified using MS columns (both Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions. Magnetic beads purification 
achieved a purity of >80%, see supplementary figure 7. 
 
Quantitative real time PCR (qPCR) 
Prior to RNA isolation, co-cultures were extensively washed with PBS in order to remove 
MAIT cells. RNA was isolated from HSC cell lysates employing RNeasy mini Kit (Qiagen, 
Hilden, Germany), purity and RNA concentration were measured with Nanodrop 
spectrophotometer (Thermo Scientific, Waltham, MA). cDNA was synthesized with 
MultiScribe reverse transcriptase, random primers, deoxyribose nucleoside triphosphate 
(dNTP) mix and RNase inhibitor (all Applied Biosystems, Foster City, CA) according to the 
following protocol, using Quanta Biotech Q Cycler II: 2 min 50°C, 10 min 95°C, followed by 
40 cycles of 15 seconds 95°C and 60 seconds 60°C. Gene expression was measured via qPCR 
using Taqman gene assays (listed in table S2). To quantify gene expression, the comparative 
CT method was used as described previously (2) using Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as internal control. 
 
Immunohistochemistry and histochemical staining of liver tissue 
Frozen, non-fixed, liver tissue samples were mounted in OCT compound, sectioned at 6 μm 
and fixed using cold acetone (5°C) for 5 minutes. Prior to staining, sections were washed in 
water to remove the OCT. 
Histochemical stains: Tissue sections were stained with Harris’s Haematoxylin and Eosin 
(Leica, Wetzlar, Germany) or Picro-Sirius Red (BDH Chemicals, Poole, UK). 
Immunocytochemistry: Sections were stained for MAIT cells using an anti Vα7.2 TCR (clone 
3C10) primary antibody (Biolegend, San Diego, CA) and visualised with the Novolink Max 
Polymer detection kit (Leica, Wetzlar, Germany).  The slides were soaked in wash buffer (Tris 
buffered saline with 0.04% Tween-20) for 5 minutes, blocked with peroxidase blocking 
solution for 5 minutes and washed in wash buffer for 5 minutes.   The slides were blocked 
for non-specific binding of the secondary layer using the kit’s protein block. Primary 
antibody (dilution 1:150) was added and incubated for 1 hour at room temperature.  The 
slides were then placed for 25 minutes in the post primary solution, 25 minutes in the 
polymer solution and developed with 3,3′ di-amino-benzidine. Slides were counterstained 
with Mayer’s Haematoxylin (Sigma Aldrich, Missouri, MO) for 3 minutes. All sections were 
dehydrated in graded industrial denatured alcohol, cleared in xylene and mounted with DPX 
(Leica, Wetzlar, Germany).  The slides were observed using an Axioskop 40 microscope and 




Supplementary figure legends 
 
Supplementary figure 1: All MAIT cell subsets are significantly reduced in patients with 
AILD 
(a) Gating strategy for MAIT cells, representative flow cytometry plots, gated on live cells. 
(b) Frequency of different lymphocyte populations in healthy controls and AILD patients. (c) 
Frequency of CD8+, CD4-/CD8-, CD4+ and CD4+/CD8+ MAIT cells in peripheral blood of AILD 
patients (n=15 (HC), n=18 (PSC), n=14 (PBC), n=10 (AIH)). Data represent mean +/- SD, 
pooled data from 4 independent experiments. *p< 0.05, **p<0.01, ***p<0.001, 
****p<0.0001 vs. healthy controls, assessed by Kruskal-Wallis test (b), or one-way ANOVA 
with Tukey’s multiple comparisons test (c). HC = healthy controls 
 
Supplementary figure 2: Expression of activation and exhaustion markers negatively 
correlates with MAIT cell frequency in AILD patients 
(a) PD-1 expression in peripheral blood MAIT cells. Surface activation and exhaustion marker 
expression in liver MAIT cells (b) and peripheral blood MAIT cells (c). (d) Intracellular IL-17A 
expression in MIAT cells following PMA/Ionokmycin stimulation (16h). (e) Spearman 
correlation between HLA-DR and TIM-3 expression and MAIT cell frequency in peripheral 
blood of patients with AILD. Data represent mean +/- SD, data from at least 3 independent 
experiments. 
 
Supplementary figure 3: Expression of IL-12R and IL-18R in MAIT cells from AILD patients 
and controls 
(a) IL-12R and IL-18R expression in MAIT cells from peripheral blood, (n=7). (c). IL-12R and 
IL-18R expression in MAIT cells from liver tissue. Data represent mean +/- SD, pooled data 
from at least 2 independent experiments. ns = not significant, assessed by One-way ANOVA 
with Tukey’s multiple comparisons test (a) or Mann-Whitney test (b). 
 
Supplementary figure 4: IL-12R expression is unchanged in MAIT cells following long-term 
cytokine stimulation 
MAIT cells from peripheral blood of healthy controls and AILD patients were stimulated with 
IL-1, IL-12 and IL-18 for 24-72h in vitro: (a) IL-12R and IL-18R MFI (n=5), (b) expression of 
surface exhaustion markers in MAIT cells, (c) MAIT cell and CD3+ frequency (n=70. (a-c) Data 
represent mean +/- SD, pooled data from 3 independent experiments. ns = not significant, 
assessed by 2way ANOVA and Tukey’s multiple comparisons test. 
 
Supplementary Figure 5: 
(a) RORt expression in MAIT cells from AILD patients following IL-12 stimulation (24-72h). 
Data represent mean +/- SD, *p<0.05 vs. unstimulated control, assessed by paires t-test or 
Kruskal-Wallis test. 
 
Supplementary figure 6: Expression of pro-inflammatory, but not pro-fibrogenic, genes is 
induced by IL-17A in primary human HSCs. 
(a) BrdU incorporation in hHSCs (n=4) after 48h co-culture with purified V7.2+ MAIT cells 
from AILD patients. (b) Relative gene expression in hHSCs following 48h treatment with IL-
17A (1ng/ml) in vitro. Data represent mean +/- SD, **p<0.01, ****p<0.0001 vs. no 
stimulation, assessed by One-way ANOVA and Sidak’s multiple comparisons test. 
Representative data of 3 independent experiments with up to 4 different HSC preparations. 
 
Supplementary figure 7: Magnetic cell separation 
(a) V7.2 expression before and after enrichment of V7.2+ MAIT cells using magnetic bead 
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% CD39+ MAIT cells
r = -0.4905
p = 0.0044

































% CD38+ MAIT cells
r = -0.8080
p = <0.0001
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Table S1: Patient characteristics 
 
  PSC PBC AIH NASH Healthy 
Cases number 46 41 21 11 21 
Age (years) median  
(range) 









(25 - 46) 
Male number (%) 35 (76) 2 (5) 7 (33) 7 (63) 15 (71) 
Female number (%) 11 (24) 39 (95) 14 (67) 4 (37) 6 (29) 
Fibroscan number 45 35 20 5 0 
Biopsy number    7  
Fibrosis stage (F0-1) number 16 17 9 3 n.a. 
Fibrosis stage (F2) number 10 3 3 2 n.a. 
Fibrosis stage (F3) number 7 6 5 3 n.a. 
Fibrosis stage (F4) number 12 9 3 2 n.a. 
Liver stiffness median  
(range) 
8.9  
(2.5 - 75) 
7.6  
(4.3 - 46) 
7.6  






Table S2: Taqman gene assays (all Applied Biosystems) 
 
ACTA2 Hs00426835_g1 
TIMP-1 Hs00171558_m1 
Col1A1 Hs00164004_m1 
CCL2 Hs00234140_m1 
LOX Hs00942480_m1 
MMP2 Hs01548727_m1 
IL-1 Hs01555410_m1 
IL-8 Hs00174103_m1 
IL-6 Hs00985639_m1 
GAPDH Hs02758991_m1 
 
 
 
 
